Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 26, 2024
Distillery Therapeutics

Increasing podocyte NDUFS4 for diabetic kidney disease

BioCentury | Sep 12, 2023
Discovery & Translation

Lurie winners show mitochondria is more than a powerhouse

Northwestern’s Navdeep Chandel and Harvard’s Vamsi Mootha share the FNIH’s 2023 prize for pioneering mitochondrial biology beyond ATP
BioCentury | Jun 4, 2019
Distillery Therapeutics

Mitochondria-targeted lonidamine for lung cancer

BioCentury | Apr 22, 2019
Distillery Therapeutics

The former diabetes drug phenformin for T cell ALL

BioCentury | Aug 16, 2018
Distillery Therapeutics

Cancer

BioCentury | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Mitochondrial complex 1 (MC-1)

BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Mitochondrial complex 1 (MC-1)

BioCentury | Oct 30, 2013
Clinical News

Lantheus reports Phase III data for imaging agent

Items per page:
1 - 10 of 16